Navigation Links
Double binding sites on tumor target may provide future combination therapy
Date:4/8/2008

PHILADELPHIA - Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer.

An increasing number of therapies targeting tumors that have proteins called epidermal growth factor receptors (EGFR) sitting on their surface are already being used in the clinic or are in late stages of development. For example, Herceptin is an established treatment for certain types of breast cancer and Erbitux and Vectibix are in use for other types of cancer. An additional drug called matuzumab is in phase II clinical trials.

Three years ago, Kate Ferguson, PhD, Assistant Professor of Physiology, and colleagues determined the precise molecular details of how Erbitux, a colorectal and head and neck cancer drug, binds to its target on cancer cells. EGFR drugs halt cell proliferation by blocking EGFRs molecular doorway, keeping hormones from binding and signaling tumor growth. X-ray crystallography provided a snapshot of the interaction between Erbitux and the extracellular component of the cancer cells receptors.

As is characteristic of many epithelial cancers - such as cancers of the colon, head and neck, breast, ovary, lung, and pancreas - the surface of cancer cells possess abnormally high levels of EGFR. In a cancer cell, an extracellular hormone binds to the outer piece of EGFR, and causes the inside part to kick off a series of reactions that signal the cancerous cell to replicate and divide.

In the present study, published in Cancer Cell, Ferguson and Merck colleagues found again using X-ray crystallography -- that matuzumab binds in a different place from Erbitux. Their binding does not overlap, and they can bind to EGFR at the same time.

These findings imply that a combination therapy using both types of EGFR drugs could be developed and tested, says Ferguson. This has important implications for the clinical use of matuzumab and for developing new therapies that target EGFR.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Gum Disease, HPV a Double Whammy
2. Uroplasty Plans to Double Sales Force During Fiscal 2009
3. Diabetics Face Doubled Risk of Heart Attack
4. Ford Launches Warriors in Pink Mustang for 09, Doubles Contributions To Race For The Cure
5. Diversified Clinical Services Doubles Field Management
6. Rate of escalator injuries to older adults has doubled
7. The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula
8. Amilpar Revenues Increase by 32% and EBITDA Doubles in 2007
9. Led by Cardiovascular Applications, Double Digit Growth Expected for Catheter Sales
10. Double Lung Transplant Better for Younger COPD Patients
11. Age-Related Macular Degeneration Doubles Heart Attack and Stroke Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions ... the United States, it’s a threat that is constantly changing and evolving. Mediaplanet's ... and offers strategies for the healthcare community to help decrease the number of ...
(Date:3/24/2017)... TX (PRWEB) , ... March 24, 2017 , ... ... clinic which can be found at 9618 Huebner Road. The clinic is the group’s ... OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, ...
(Date:3/24/2017)... Diego, Calif. (PRWEB) , ... March 24, 2017 ... ... has raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... the instant demand for the product – with nearly 2,000 consumers (and counting) ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The law ... White Plains, N.Y., is pleased to announce Westchester resident Lauren C. Enea has joined ... clerk for the firm, will concentrate her practice in elder law, Medicaid planning and ...
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... -- FinancialBuzz.com News Commentary  ... According to new data published ... the legal cannabis market is projected to continue to grow ... from the current presidential administration. The report created by Arcview,s ... of growth in this industry are the passage and subsequent ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... their offering. ... pipeline is very strong with a total of 97 drug candidates. Pharma ... Sanofi are involved in the development of the IPF therapeutics. The IPF ... III stage, 15 are in Phase II stage, 12 are in Phase ...
Breaking Medicine Technology: